Table 2.
Ongoing CAR cell therapy clinical trials in PDAC
| Target | Trial | Phase | Trial participants | Trial name | Progress | Institution (location) |
|---|---|---|---|---|---|---|
| CCT301-59 | NCT03960060 | I | 18 | A Study of CCT301-59 CAR T Therapy in Adult Subjects With Recurrent or Refractory Solid Tumors (CAR) | active, not yet recruiting | Shanghai Zhongshan Hospital (China) |
| CCT303-406 | NCT04511871 | I | 15 | A Phase I Trial of CCT303-406 in Patients With Relapsed or Refractory HER2 Positive Solid Tumors | recruiting | Shanghai Zhongshan Hospital (China) |
| CD22 | NCT04556669 | I | 30 | Anti-PD-L1 Armored Anti-CD22 CAR-T/CAR-TILs Targeting Patients With Solid Tumors | recruiting | Hebei Senlang Biotechnology Inc., Ltd. (China) |
| CD70 | NCT02830724 | I/II | 2 | Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers | suspended | National Cancer Institute (NCI) (USA) |
| CEA | NCT02349724 | I | 75 | A Clinical Research of CAR T Cells Targeting CEA Positive Cancer | unknown | Southwest Hospital (China) |
| CEA | NCT04348643 | I/II | 167 | Safety and Efficacy of CEA-Targeted CAR T Therapy for Relapsed/Refractory CEA+ Cancer | recruiting | Chongqing Precision Biotech Co., Ltd (China) |
| CEA | NCT04037241 | II/III | 167 | Study of Anti-CEA CAR T + Chemotherapy VS Chemotherapy Alone in Patients With CEA+ Pancreatic Cancer & Liver Metastases | not yet recruiting | Sorrento Therapeutics, Inc. (USA) |
| CEA | NCT03818165 | I | 6 | Phase 1b Study of CAR2Anti-CEA CAR T Cell Hepatic Infusions for Pancreatic Carcinoma Patients With CEA + Liver Metastases (AntiCEA_CART) | active, not yet recruiting | Sorrento Therapeutics, Inc. (USA) |
| CEA | NCT03682744 | I | 18 | CAR T Intraperitoneal Infusions for CEA-Expressing Adenocarcinoma Peritoneal Metastases or Malignant Ascites (IPC) | active, not yet recruiting | Sorrento Therapeutics, Inc. (USA) |
| CEA | NCT02850536 | I | 5 | CAR T Hepatic Artery Infusions or Pancreatic Venous Infusions for CEA-Expressing Liver Metastases or Pancreas Cancer (HITM-SURE) | active, not yet recruiting | University of Colorado, Denver (USA) |
| Claudin18.2 | NCT04404595 | I | 30 | Claudin18.2 CAR T (CT041) in Patients With Gastric or Pancreatic Cancer | recruiting | Carsgen Therapeutics, Ltd. |
| Claudin18.2 | NCT03874897 | I | 70 | Chimeric Antigen Receptor T Cells Targeting claudin18.2 in Solid Tumors. | recruiting | Peking University (China) |
| Claudin18.2 | NCT03159819 | NA | 24 | Clinical Study of CAR-CLD18 T Cells in Patients With Advanced Gastric Adenocarcinoma and Pancreatic Adenocarcinoma | recruiting | Changhai Hospital (China) |
| Claudin18.2 | NCT04404595 | I | 30 | Claudin18.2 CAR T (CT041) in Patients With Gastric or Pancreatic Cancer | recruiting | Carsgen Therapeutics, Ltd. |
| Claudin18.2 | NCT03890198 | I | 2 | A Phase 1 Study of LCAR-C182A Cells in the Treatment of Advanced Gastric Cancer and Pancreatic Ductal Adenocarcinoma | terminated | First Affiliated Hospital Xi'an Jiaotong University (China) |
| Claudin18.2/CD19/BCMA/GPC3 | NCT03302403 | NA | 18 | Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant Tumors | active, not yet recruiting | First Affiliated Hospital of Wenzhou Medical University (China) |
| EGFR | NCT03182816 | I/II | 40 | CTLA-4 and PD-1 Antibodies Expressing EGFR-CAR T Cells for EGFR Positive Advanced Solid Tumor | unknown | Shanghai Cell Therapy Research Institute (China) |
| EGFR | NCT01869166 | I/II | 60 | Treatment of Chemotherapy Refractory EGFR (Epidermal Growth Factor Receptor) Positive Advanced Solid Tumors (CART-EGFR) (CART-EGFR) | unknown | Chinese PLA General Hospital (China) |
| EpCAM | NCT03013712 | I/II | 60 | A Clinical Research of CAR T Cells Targeting EpCAM Positive Cancer (CARTEPC) | unknown | First Affiliated Hospital of Chengdu Medical College (China) |
| EpCam/TM4SF1 | NCT04151186 | NA | 72 | A Clinical Study on the Safety and Efficacy of CAR T Therapy for the TM4SF1- and EpCAM-positive Solid Tumors | not yet recruiting | Shanghai Biomed-union Biotechnology Co., Ltd. (China) |
| GD2 | NCT02992210 | I/II | 100 | Study on GD2 Positive Solid Tumors by 4SCAR-GD2 | unknown | Shenzhen Geno-Immune Medical Institute (China) |
| HER2 | NCT04650451 | I | 220 | Safety and Activity Study of HER2-Targeted Dual Switch CAR T Cells (BPX-603) in Subjects With HER2-Positive Solid Tumors | recruiting | Bellicum Pharmaceuticals (USA) |
| HER2 | NCT04660929 | I | 18 | CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors | recruiting | Carisma Therapeutics Inc (USA) |
| HER2 | NCT03740256 | I | 45 | Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors (VISTA) | recruiting | Baylor College of Medicine (USA) |
| HER2 | NCT01935843 | I/II | 10 | Treatment of Chemotherapy Refractory Human Epidermal growth Factor Receptor-2(HER-2) Positive Advanced Solid Tumors (CART-HER-2) | unknown | Chinese PLA General Hospital (China) |
| HER2 | NCT04660929 | I | 18 | CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors | recruiting | Carisma Therapeutics Inc (USA) |
| HER2 | NCT02713984 | I/II | NA | A Clinical Research of CAR T Cells Targeting HER2 Positive Cancer | withdrawn | Southwest Hospital (China) |
| MSLN | NCT02959151 | I/II | 20 | A Study of Chimeric Antigen Receptor T Cells Combined With Interventional Therapy in Advanced Liver Malignancy | unknown | Shanghai Cancer Hospital (China) |
| MSLN | NCT03497819 | I | 10 | Autologous CARTmeso/19 Against Pancreatic Cancer | unknown | First Affiliated Hospital of Wenzhou Medical University (China) |
| MSLN | NCT04203459 | NA | 80 | The Mechanism of Enhancing the Anti-tumor Effects of CAR T on PC by Gut Microbiota Regulation | recruiting | First Affiliated Hospital of Harbin Medical University (China) |
| MSLN | NCT03545815 | I | 10 | Study of CRISPR-Cas9 Mediated PD-1 and TCR Gene-knocked Out Mesothelin-directed CAR T Cells in Patients With Mesothelin Positive Multiple Solid Tumors. | recruiting | Chinese PLA General Hospital (China) |
| MSLN | NCT03323944 | I | 18 | CAR T cell Immunotherapy for Pancreatic Cancer | recruiting | University of Pennsylvania (USA) |
| MSLN | NCT03182803 | I/II | 40 | CTLA-4 and PD-1 Antibodies Expressing Mesothelin-CAR T Cells for Mesothelin Positive Advanced Solid Tumor | unknown | Shanghai Cell Therapy Research Institute (China) |
| MSLN | NCT02465983 | I | 4 | Pilot Study of Autologous T-cells in Patients With Metastatic Pancreatic Cancer | terminated | University of Pennsylvania (USA) |
| MSLN | NCT03638193 | NA | 10 | Study of Autologous T-cells in Patients With Metastatic Pancreatic Cancer | recruiting | The First Affiliated Hospital with Nanjing Medical University (China) |
| MSLN | NCT03747965 | I | 10 | Study of PD-1 Gene-knocked Out Mesothelin-directed CAR T Cells With the Conditioning of PC in Mesothelin Positive Multiple Solid Tumors | unknown | Chinese PLA General Hospital (China) |
| MSLN | NCT03497819 | I | 10 | Autologous CARTmeso/19 Against Pancreatic Cancer | unknown | First Affiliated Hospital of Wenzhou Medical University (China) |
| MSLN | NCT01583686 | I/II | 15 | CAR T cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer | terminated | National Cancer Institute (NCI) (USA) |
| MSLN | NCT03638206 | I/II | 73 | Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies | recruiting | The First Affiliated Hospital of Zhengzhou University (China) |
| MSLN | NCT02580747 | I | 20 | Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART-meso | unknown | Chinese PLA General Hospital (China) |
| MSLN | NCT03030001 | I/II | 40 | PD-1 Antibody Expressing CAR T Cells for Mesothelin Positive Advanced Malignancies | unknown | Ningbo Cancer Hospital (China) |
| MSLN | NCT02706782 | I | 30 | A Study of Mesothelin Redirected Autologous T Cells for Advanced Pancreatic Carcinoma (meso-CART) | unknown | Shanghai GeneChem Co., Ltd. (China) |
| MSLN/CD19 | NCT03497819 | I | 10 | Autologous CARTmeso/19 Against Pancreatic Cancer | unknown | First Affiliated Hospital of Wenzhou Medical University (China) |
| MSLN/PSCA/CEA/HER2/MUC1/EGFRvIII | NCT03267173 | I | 10 | Evaluate the Safety and Efficacy of CAR T in the Treatment of Pancreatic Cancer. | unknown | First Affiliated Hospital of Harbin Medical University (China) |
| MUC1 | NCT02839954 | I/II | 10 | CAR-pNK Cell Immunotherapy in MUC1 Positive Relapsed or Refractory Solid Tumor | unknown | The First People's Hospital of Hefei (China) |
| MUC1 | NCT03179007 | I/II | 40 | CTLA-4 and PD-1 Antibodies Expressing MUC1-CAR T Cells for MUC1 Positive Advanced Solid Tumor | unknown | Shanghai Cell Therapy Research Institute (China) |
| MUC1 | NCT02587689 | I/II | 20 | Phase I/II Study of Anti-Mucin1 (MUC1) CAR T Cells for Patients With MUC1+ Advanced Refractory Solid Tumor | unknown | The First People's Hospital of Hefei (China) |
| MUC1 | NCT03633773 | I/II | 9 | Safety and Efficacy Evaluation of MUC-1 CART in the Treatment of Intrahepatic Cholangiocarcinoma | recruiting | Second Affiliated Hospital, School of Medicine, Zhejiang University (China) |
| PSCA | NCT02744287 | I/II | 151 | Safety and Activity Study of PSCA-Targeted CAR T Cells (BPX-601) in Subjects With Selected Advanced Solid Tumors | recruiting | Bellicum Pharmaceuticals (USA) |
CEA, carcinoembryonic antigen; BCMA, B cell maturation antigen; EGFR, epidermal growth factor receptor; EpCAM, epithelial cell adhesion molecule; GD2, disialoganglioside; GPC3, Glypican 3; HER2, human epidermal growth factor receptor 2; MSLN, mesothelin; PSCA, prostate stem cell antigen; MUC1, mucin 1.